Minovia Therapeutics Announces FDA Clearance of IND Application for a Phase Ib Clinical Trial of MNV
MNV-201 is a mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondria
In pre-clinical studies, MNV-201 demonstrated improved engraftment and bone marrow reconstitution potential of patient derived hematopoietic stem cells
In vitro data also demonstrated improved ability to differentiate to erythroid cells, supporting potential for improvement in biomarkers of anemia
HAIFA, Israel, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd, a clinical stage biopharmaceutical company advancing mitochondrial cell therapies for primary and secondary mitochondrial diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for MNV-201, an autologous hematopoietic stem cell product augmented with allogeneic mitochondria. The IND supports the initiation of a Phase Ib dose exploration clinical trial of MNV-201 in patients with Low Risk Myelodysplastic Syndrome (MDS).
Anemia is a common and serious symptom in patients with low-risk myelodysplastic syndrome (LR-MDS), affecting almost 90% of cases and is often the primary characteristic of the disease. Anemia in MDS can have a negative impact on quality of life and may correlate with decreased progression-free survival and overall survival.
“The FDA’s clearance of our IND marks an important achievement for Minovia, allowing us to clinically evaluate our allogeneic mitochondrial cell therapy approach and proceed with the Phase Ib clinical program for this first-in-class allogeneic mitochondrial therapy for low risk MDS patients,” said Natalie Yivgi Ohana, PhD, CEO of Minovia. “We are pleased to have safely dosed two MDS patients enrolled in an ongoing study under the Israeli Ministry of Health. We look forward to treating additional patients under this IND, as well as to learning about the potential of MAT to improve anemia in this patient population.”
The Phase Ib clinical trial is an open-label, dose exploration study to evaluate the safety and efficacy of MNV-201 in subjects with low risk MDS. This trial will continue our campaign to evaluate dose exploration and safety of single or repeat dosing of MNV-201. The trial will also enable assessment of efficacy in improving anemia and durability of response. The study is expected to enroll at least three patients each in the low, medium and high dose cohorts, and up to a total of 15 patients in total. For more information visit clinicaltrials.gov.
About MNV-201
MNV-201 is an autologous hematopoietic stem cell product enriched with allogeneic mitochondria. MNV-201 aims to restore mitochondrial function in low risk MDS patient hematopoietic stem cells, resulting in improved differentiation to erythroid lineage with the potential to improve anemia. Preclinical research suggests the potential for safe dosing with low immunogenicity risk and scalable manufacturing to address the significant number of patients who are potentially eligible for MNV-201 therapy.
About Minovia Therapeutics
Minovia Therapeutics Ltd. is a clinical stage biotechnology company advancing mitochondrial cell therapies for primary-genetic and age-related mitochondrial diseases. Minovia's clinical stage product candidate, MNV-201, is composed of mobilized peripheral blood, autologous CD34+ cells enriched with allogeneic, cryopreserved placental derived mitochondria, produced by Minovia's proprietary Mitochondrial Augmentation Technology (MAT). The enrichment of hematopoietic stem cells with healthy and functional mitochondria aims to restore stem cells function of patients suffering mitochondrial dysfunction, caused both by mtDNA mutations or deletions in pediatric patients suffering from primary mitochondrial diseases, or in adults with age-related bone marrow failure disorders. MNV-201 is currently in clinical studies for pediatric patients with single-large scale mtDNA deletion syndromes (Pearson Syndrome and Kearn Sayre Syndrome) with four patients successfully dosed; and in Low Risk Myelodysplastic Syndrome. For more information, please visit www.minoviatx.com or follow the Company LinkedIn.
About Low Risk Myelodysplastic Syndrome
Myelodysplastic syndromes (MDS) are a group of bone marrow failures that occur when the blood-forming cells in the bone marrow become abnormal leading to an abnormal differentiation and production of one or more blood cell types. Patients with MDS collectively have a high symptom burden and are also at risk of death from complications of cytopenias or progression to acute myeloid leukemia (AML). MDS is generally a disease that develops with aging; the median age at diagnosis of MDS is ~70 years.
Mitochondrial Dysfunction in MDS: Scientific literature shows a correlation between mitochondrial dysfunction and MDS progression. It is known that ineffective hematopoiesis in MDS results from increased susceptibility of clonal myeloid progenitors to apoptosis. This may be triggered by intrinsic factors, such as mitochondrial polarization due to iron retention in ringed sideroblasts. A subset of MDS patients present with sideroblastic anemia, a phenotype common in Pearson Syndrome patients and which implicates mitochondrial dysfunction of HSPCs as part of the pathology of MDS.
Contact Information: Natalie Yivgi Ohana, Co-Founder and CEO
Phone: +972-74-7039954
Email: info@minoviatx.com
- Sportradar Appoints Behshad Behzadi as Company’s Chief Technology Officer and Chief Artificial Intel
- 还在忍受难闻的消毒水味?上海的精品超市在卖这些
- 韩国女团X:IN实力圈粉 俘获全球众粉丝喜爱
- 人民艺术家、国家一级美术师孙长英
- 软胶囊专用明胶,冻力是多少?为你提供专用服务方案
- 白山方大集团召开315消费者权益日暨“白山方大诚信日”庆祝大会
- 平安产险安徽分公司:“乡风文明100行动”落地广德市佛堂村
- 旺旺邦德黑咖啡聚焦健身人群 首次亮相IWF国际健身展
- 中信银行太原分行获老年客户感谢信
- 引领牙齿美学修复技术变革 Venust皓昕3D打印更健康
- 消散暑气重新找回好胃口 麻辣or清爽美食全都要
- 双塔食品与联合利华推出植物肉“海鲜风味排”
- 9月10日,佛山见!2024华韵视听大会将在佛山举行
- 农发行衡阳市分行:备足信贷资金 确保夏粮收购“粒归仓”
- 《中俄文化推荐官》官方重点推荐艺术家—王有德
- ThreatLocker® Unveils New Managed Detection and Response (MDR) Service with the World
- 联想集团:2024/25财年第一季度业绩
- 陪伴就诊APP平台的需求,主要来源于这2个方面!
- 蒙迪欧VS迈腾VS帕萨特,谁才是B级车性能标杆?
- 2024年律所管理系统优选,Alpha系统律所管理功能获用户好评
- Hitachi Energy’s HVDC technology to power Marinus Link, a key step toward Australia’s Net Zero ambit
- instagram营销软件-ins云控群发软件,海外精准博主爆粉神器
- 【福州爱尔】泡温泉一时爽,过后眼睛又红又肿
- “妈妈,为什么我的眼睛这么小?”福州爱尔公益之花绽放让小睑裂患儿从疑惑迈向光明的希望
- 《党在我心中》非凡成就杰出军旅艺术家张金铭
- 临商银行兰陵支行积极开展电子支付惠企利民宣传活动
- 礼献中秋,共叙团圆 | 同仁堂健康中秋臻礼浓情献市
- 计提工资和发放工资的区别
- 华贵保险召开2024年度防范电信网络诈骗工作部署专项会议
- 史迪姆:九年坚守,只为守护健康初心————浙江史迪姆生物科技有限公司 范汉东
推荐
- 一个“江浙沪人家的孩子已经不卷学习了”的新闻引发议论纷纷 星标★ 来源:桌子的生活观(ID:zzdshg) 没 资讯
- 透过数据看城乡居民医保“含金量” 缴费标准是否合理? 记者从国家医保局了解到,近期,全国大部分地区 资讯
- 看新东方创始人俞敏洪如何回应董宇辉新号分流的? (来源:中国证券报) 东方甄选净利润大幅下滑 资讯
- 新增供热能力3200万平方米 新疆最大热电联产项目开工 昨天(26日),新疆最大的热电联产项目—&md 资讯
- 产业数字化 为何需要一朵实体云? 改革开放前,国内供应链主要依靠指标拉动,其逻 资讯
- 王自如被强制执行3383万 据中国执行信息公开网消息,近期,王自如新增一 资讯
- 大家一起关注新疆乌什7.1级地震救援见闻 看到热气腾腾的抓饭马上就要出锅、村里大家 资讯
- 私域反哺公域一周带火一家店! 三四线城市奶茶品牌茶尖尖两年时间做到GMV 资讯
- 周星驰新片《少林女足》在台湾省举办海选,吸引了不少素人和足球爱好者前来参加 周星驰新片《少林女足》在台湾省举办海选,吸 资讯
- 海南大学生返校机票贵 有什么好的解决办法吗? 近日,有网友在“人民网领导留言板&rdqu 资讯